# Supplementary Information

### **Berberine Nanoparticles for Promising Sonodynamic**

## Therapy on HeLa Xenograft Tumor

Hanqing Liu,<sup>a</sup> Tingting Zheng,<sup>a,\*</sup> Ziqian Zhou,<sup>a</sup> Azhen Hu,<sup>a</sup> Minghua Li,<sup>a</sup> Zhuxia Zhang,<sup>a</sup> Guangyin Yue,<sup>b</sup> Huanhuan Feng,<sup>c</sup> Yawen An,<sup>d</sup> Jiao Peng,<sup>e,\*</sup> and Yun Chen<sup>a,\*</sup>

a Shenzhen Key Laboratory for Drug Addiction and Medication Safety, Peking University Shenzhen Hospital, Shenzhen Peking University – The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, China.

b Department of Pathology, Peking University Shenzhen Hospital, Shenzhen 518036, China.

c Research Centre of Printed Flexible Electronics, School of Materials Science and Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China.

d The State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China.

e Department of Parmacy, Peking University Shenzhen Hospital, Shenzhen 518036, China.

\*These authors correspond to this work: dr.tingting.zheng@gmail.com, pengjiao153@163.com, prof\_yunchen@yeah.net.

Table of Contents		Page
Part 1	SEM morphology study of BBR and BBRNPs	2
Part 2	Viscera morphology after excess BBRNPs injection	2
Part 3	Tumour ultrasound contrast imaging	2
Part 4	Data analysis of ultrasound contrast imaging	3
Part 5	Histological analysis of FUS damaged cancer tissue	3
Part 6	HeLa xenograft mice photographs	4

### Part 1. SEM morphology study of BBR and BBRNPs



**Figure S1.** (A-1) to (A-3) present BBR crystals in netural buffer with irregular microstructure, (B-1) to (B-2) present BBRNPs monodispersed nanostructure .

#### Part 2. Viscera morphology after excess BBRNPs injection



Figure S2. Images of viscera morphology after BBR excess dosage intravenous injection.



#### Part 3. Tumour ultrasound contrast imaging

**Figure S3.** Ultrasound contrast imaging of tumor blood vessels. 1-7 indicate different mice No. at each group. (N = 7, means  $\pm$  SD, \* P < 0.05, vs control group. Ctrl: control group, BBR: BBR group, US: ultrasound group, SDT: BBR mediated SDT group.)



**Figure S4.** (A) Representative images of ultrasound examination and microbubble imaging. Left peak shows an example of contrast mean power vs time to peak after microbubbles intravenous injection. Right figures show ultrasonograpy and power Doppler images after microbubbles injection. Red arrow pointed to the maximum contrast mean power of M(B) Time of maximum microbuble accumulation according to the value of contrast mean power. (N = 7, means  $\pm$  SD, \* P < 0.05, vs control group. Ctrl: control group, BBR: BBR group, US: ultrasound group, SDT: BBR mediated SDT group.)



Part 5. Histological analysis of FUS damaged cancer tissue

Part 4. Data analysis of ultrasound contrast imaging

**Figure S5.** (A) H&E staining of pathological sections of burned area of focused ultrasound where is pointed by white arrow. (B) Pathological slides of damaged blood vessels in cancer tissue which is

caused by ultrasound mediats BBRNPs cavitation (black arrow). Left column shows objective images with 20 times magnification, while right column shows 40 times magnification images.

Part 6. HeLa xenograft mice photographs



**Figure S6.** HeLa xenograft mouse photoes taken before and after treatement of drug intraperitoneal injection.